Phase II study of TS-1 / oxaliplatin(G-SOX) plus bevacizumab treatment for elderly advanced colorectal cancer patients.(GIANTS study) - GIANTS study

niversity of Miyazaki Hospital.0 个研究点目标入组 50 人开始时间: 2012年11月1日最近更新: 2023年10月17日

适应症

试验速览

暂无简介。

•1. History of the severe hypersensitivity 2. Active infection and inflammation 3. Patients have gastrointestinal perforation or bleeding 4. High grade peritoneal metastasis 5. Severe complications 6. Symptomatic or asymptomatic but treated heart disease 7. Patients have hemoptysis 8. Patients have peripheral sensory neuropathy 9. Watery stools or diarrhea 10. Massive pleural or abdominal effusion 11. Metastasis to CNS 12. History of the perforation of the digestive tract within 6 months before registration 13. History of the thromboembolism, brain infarction, lung infarction, brain infarction or pneumonitis 14. operation within 28 days 15. artificial anus within 14 days 16. congenital bleeding predisponency or abnormality of hemostasis 17. Patients have anticoagulant agent 18. synchronous or metachronous (within 5 years) malignancy other than carcinoma in situ 19. Patients under treatment with flucytosine 20. With contraindicate TS-1, L-OHP, Bevacizumab 21. Patients under treatment with steroid 22. High-grade stricture 23. Pregnant or lactating woman or no birth-control 24. Other patients who are unfit for the study as determined by the attending physician.

发起方

niversity of Miyazaki Hospital.